Michaela Prchal-Murphy
Overview
Explore the profile of Michaela Prchal-Murphy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karjalainen A, Witalisz-Siepracka A, Prchal-Murphy M, Martin D, Sternberg F, Krunic M, et al.
Cell Mol Life Sci
. 2025 Mar;
82(1):98.
PMID: 40025196
Tyrosine kinase 2 (TYK2) deficiency and loss or inhibition of kinase activity in men and mice leads to similar immune compromised phenotypes, predominantly through impairment of interferon (IFN) and interleukin...
2.
Prchal-Murphy M, Zehenter J, Fischer M, Pirabe A, Themanns M, Afrashteh B, et al.
Front Pharmacol
. 2025 Jan;
15():1444311.
PMID: 39850556
Objective: The expanding field of hematopoietic cell transplantation (HCT) for non-malignant diseases, including those amenable to gene therapy or gene editing, faces challenges due to limited donor availability and the...
3.
Jelencic V, Sestan M, Kavazovic I, Lenartic M, Marinovic S, Holmes T, et al.
Nat Immunol
. 2024 Nov;
26(1):146.
PMID: 39562744
No abstract available.
4.
Trifinopoulos J, List J, Klampfl T, Klein K, Prchal-Murphy M, Witalisz-Siepracka A, et al.
Haematologica
. 2024 Oct;
PMID: 39385738
Despite major therapeutic advances in the treatment of acute lymphoblastic leukemia (ALL), resistances and long-term toxicities still pose significant challenges. Cyclins and their associated cyclin-dependent kinases are one focus of...
5.
Lind J, Aksoy O, Prchal-Murphy M, Fan F, Fulciniti M, Stoiber D, et al.
Blood Cancer J
. 2024 Aug;
14(1):138.
PMID: 39160158
Deregulation of transcription factors (TFs) leading to uncontrolled proliferation of tumor cells within the microenvironment represents a hallmark of cancer. However, the biological and clinical impact of transcriptional interference, particularly...
6.
Mayer I, Doma E, Klampfl T, Prchal-Murphy M, Kollmann S, Schirripa A, et al.
Blood
. 2024 Apr;
144(2):156-170.
PMID: 38684032
Hematopoietic stem cells (HSCs) are characterized by the ability to self-renew and to replenish the hematopoietic system. The cell-cycle kinase cyclin-dependent kinase 6 (CDK6) regulates transcription, whereby it has both...
7.
Kollmann S, Grausenburger R, Klampfl T, Prchal-Murphy M, Bastl K, Pisa H, et al.
Blood
. 2021 Jul;
138(23):2347-2359.
PMID: 34320169
The transcription factors signal transducer and activator of transcription 5A (STAT5A) and STAT5B are critical in hematopoiesis and leukemia. They are widely believed to have redundant functions, but we describe...
8.
Demiroz D, Platanitis E, Bryant M, Fischer P, Prchal-Murphy M, Lercher A, et al.
PLoS Pathog
. 2021 Jul;
17(7):e1009697.
PMID: 34237114
Listeria monocytogenes (L. monocytogenes) is a food-borne bacterial pathogen. Innate immunity to L. monocytogenes is profoundly affected by type I interferons (IFN-I). Here we investigated host metabolism in L. monocytogenes-infected...
9.
Fujimoto M, Kamiyama M, Fuse K, Ryuno H, Odawara T, Furukawa N, et al.
Cancer Sci
. 2021 Feb;
112(4):1633-1643.
PMID: 33565179
Tumor metastasis is the leading cause of death worldwide and involves an extremely complex process composed of multiple steps. Our previous study demonstrated that apoptosis signal-regulating kinase 1 (ASK1) deficiency...
10.
Maurer B, Brandstoetter T, Kollmann S, Sexl V, Prchal-Murphy M
Haematologica
. 2020 Aug;
106(10):2624-2632.
PMID: 32855282
Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are considered a breakthrough in cancer therapy. Currently approved for breast cancer treatment, CDK4/6 inhibitors are extensively tested in other cancer subtypes. Frequently...